Shukra Pharmaceuticals Ltd — Important, 07-05-2026: Company Update

Shukra Pharmaceuticals confirmed no deviation in how it is using funds raised from 46.43 lakh convertible warrants. The company received ₹3.95 Cr, representing 25% of the total ₹15.79 Cr consideration from this preferential issue. These funds are being deployed exactly as outlined for critical business needs, including working capital, debt repayment, capital expenditure, and general corporate purposes. This assurance, reviewed by the Audit Committee, confirms the company's commitment to transparent and proper utilization of investor capital for its stated growth objectives.